Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) are becoming increasingly important in the management of heart failure (HF) due to their therapeutic effects in patients with or without diabetes. This evidence concerns the gene SLC5A2 and hydrops fetalis.